Aurora, Copeia launch English medical cannabis system

Executive Summary

• Aurora Cannabis Inc. has launched the English-language version of the Physician Experience Platform (PEP) in collaboration with Copeia, expanding access to peer-reviewed medical cannabis case studies for healthcare professionals globally.
• The platform provides over 130 anonymized case studies containing detailed clinical data, including patient history, symptoms, therapeutic outcomes, dosage, and product information, to aid in informed prescribing.
• Initial access is restricted to verified healthcare professionals in Canada, the UK, Poland, Malta, the Czech Republic, Australia, and New Zealand, with future plans to allow user-generated content uploads.

Key Details

• Platform Launch: English version of the Physician Experience Platform (PEP) launched following the successful German rollout in early 2024.
• Content Volume: More than 130 anonymized case studies are currently available on the platform.
• Data Granularity: Each case study includes patient history, treated symptoms, therapeutic outcomes, dosage and product data, and documentation of other therapies before and during cannabis-based medicine treatment.
• Search Functionality: Healthcare providers can search for local product recommendations based on those used in similar case studies.
• Access Control: The platform is gated by DocCheck login access to ensure only verified health care professionals can view the content.
• Geographic Availability: Initially available to physicians in Canada, United Kingdom, Poland, Malta, the Czech Republic, Australia, and New Zealand.
• Future Roadmap: The platform is currently read-only; a future version is expected to allow physicians worldwide to upload and share case studies to create an international medical cannabis study database.
• Strategic Partners: Aurora Cannabis Inc. and Copeia (German health care technology leader).

Notable Quotes

• "The development of the English PEP marks a major milestone for international physician education in medical cannabis, and Aurora is proud to be at the forefront of this work... By opening access to a broader audience of health care professionals, we're setting a new standard in peer-led clinical knowledge sharing that we believe will have direct impact on the prescribing of medical cannabis." — Dr. Stephanie Lunn, Director of Medical and Patient Affairs at Aurora Cannabis.
• "Physicians have long faced challenges prescribing medical cannabis... due to its limited integration into established health care education and processes. Uncertainty and skepticism remain, underscoring the need for real-world data to enable personalized care and informed prescribing." — Garvin Hirt, CEO of Copeia.